Compare ING Groep NV (ING) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Johnson & Johnson — how do they compare? ING Groep NV trades at $35.63 (market cap $101.22B), while Johnson & Johnson trades at $257.83 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 6.2× ING Groep NV's market cap, and ING Groep NV pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| ING | JNJ | |
|---|---|---|
Market Cap | $101.22B | $626.09B |
Sector | Financials | Health |
52-Week High | $35.92 | $267.24 |
52-Week Low | $23.66 | $172.78 |
Dividend Yield | 3.73% | 2.06% |
Volume | — | 6,156,228 |
Enterprise Value | — | $654.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $35.24, down 1.23% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 62.5% buy ratings. Recent news highlights strategic acquisitions and a dividend payment scheduled for August 2026.
The outlook for ING is favorable, supported by earnings momentum and upward guidance revisions. Key opportunities include growth in net interest income and fee-based revenue. Risks involve persistent negative operating cash flows and sensitivity to European economic conditions. The stock presents a value proposition with a P/E of 13.24, though cash flow trends warrant monitoring.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
